COL18A1 and non-small cell lung carcinoma: Recombinant human endostatin is an angiogenic inhibitor with no cytotoxicity approved by the Chinese FDA for treating various cancers, including NSCLC.337,546 However, the clinical application of endostatin is not very accessible due to poor stability and solubility, short half-lives, and difficult production problems.